|
|
News Breaks | | | | December 13, 2012 | | 07:35 EDT |  | SNTA | Synta Pharmaceuticals announces $60M registered direct common stock offering
Synta Pharmaceuticals has entered into common stock purchase agreements with members of its Board of Directors and various institutional investors for the sale of 7,000,000 shares of its common stock in an issuer directed, registered direct offering. Shares were priced at $8.60, the consolidated closing bid price as of December 12 for gross proceeds of approximately $60M. No underwriter or placement agent was used in this transaction. The offering is expected to close on or about December 18, subject to satisfaction of customary closing conditions. Net proceeds from the offering will be used to fund Synta's operations, including, research and development, clinical trials, manufacturing, intellectual property protection and enforcement, and working capital, and for other general corporate purposes. | |
|
News For SNTA From The Last 14 Days Check below for free stories on SNTA the last two weeks. |
|
|
| May 10, 2013 | | 12:32 EDT |  | SNTA | Options with increasing implied volatility: SNTA BKS FIO QIHU VMED
| | | May 8, 2013 | | 08:00 EDT |  | SNTA | Synta downgraded to Market Perform from Outperform at BMO Capital
 Subscribe for More Information | | | May 7, 2013 | | 12:16 EDT | | SNTA | Synta downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgraded Synta Pharmaceuticals citing uncertainty followinig the resignation of Dr. Ramachandra. | | | May 6, 2013 | | 17:58 EDT | | SNTA | Synta Pharmaceuticals R&D president Ramachandra resigns
Subscribe for More Information | |
|
|
|
|
|
|
